KRAS and non-small cell lung carcinoma: Gefitinib (1 μM) did not inhibit PI3K activation in HCT116 cells, although gefitinib inhibited the complexing of K-Ras/PI3K and K-Ras/Raf in NSCLC K-Ras/PTEN or K-Ras/PIK3CA co-mutant cells [7].